BI-1808

· BioInvent International AB

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI-1808, covering 2026-02-18 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) [Phase 1, Phase 2]

See pricing